The Metastasis-Associated microRNA miR-516a-3p Is a Novel Therapeutic Target for Inhibiting Peritoneal Dissemination of Human Scirrhous Gastric Cancer

Yoshifumi Takei1,2, Misato Takigahira3, Keichiro Mihara4, Yuzo Tarumi5, and Kazuyoshi Yanagihara3,6

Abstract

Although aberrant microRNA (miRNA) is expressed in different types of human cancer tissues, its physiologic role and the relevance of tumorigenesis and metastasis are still largely unknown. Here, we defined miRNAs involved in cancer metastasis (metastamirs) using an established mouse model for peritoneal dissemination of human scirrhous gastric carcinoma cells. Highly metastatic derivatives (44As3 cells) were derived from the parental cells originally isolated from patients (HSC-44PE cells). Using microarray analysis to identify differentially expressed miRNAs in 44As3 and HSC-44PE cells, we focused on miR-516a-3p as a candidate antimetastatic miRNA (antimetastamir) whose functions in cancer had not been studied. We confirmed attenuated expression of miR-516a-3p in 44As3 cells compared with HSC-44PE cells by Northern blot analysis and quantitative reverse transcriptase PCR. Stable ectopic overexpression in 44As3-miR-516a-3p cells permitted identification of sulfatase 1 as a direct target of the miRNA, through use of the isobaric tagging reagent iTRAQ and the QSTAR Elite Hybrid LC-MS/MS system. Sulfatase 1 is known to remove 6-O-sulfates from heparan sulfate proteoglycans on the cell surface, causing release of membrane-bound Wnt ligands from cells. Consistent with this function, Western blot analyses revealed high levels of Wnt3a, Wnt5a, and nuclear β-catenin accumulation in 44As3 cells but relatively reduced levels in 44As3-miR-516a-3p cells. Notably, orthotopic inoculation of nude mice with 44As3-miR-516a-3p cells yielded significantly longer survival periods compared with mice inoculated with control 44As3 cells. Through atelocollagen-mediated delivery of an miR-516a-3p expression vector into orthotopic 44As3 tumors, we documented its feasibility as a treatment agent. Our findings define the miRNA miR-516a-3p as an antimetastamir with potential therapeutic applications in blocking metastatic dissemination of gastric cancers. Cancer Res; 71(4): 1442–53. ©2010 AACR.

Introduction

MicroRNAs (miRNA) are a class of short, conserved, non-coding RNAs that play important regulatory roles in post-transcriptional repression (1–3). These are fundamental gene regulators that control proliferation, differentiation, and apoptosis during development (1–3). They target a large number of mRNAs and induce mRNA degradation or inhibition of translation by targeting the 3′-untranslated regions (UTR; ref. 2). These broad functions suggest that miRNAs may contribute to a range of diseases, including cancers, and recent studies indicate that miRNAs can function as tumor suppressors and oncogenes (1, 4). The development of microarray platforms for the analysis of miRNA expression revealed that multiple miRNAs are aberrant or lacking in human malignancies (5, 6).

Gastric cancer is a major cause of deaths from cancer, particularly on the basis of peritoneal metastasis (7). Scirrhous gastric carcinoma, a diffusely infiltrating type of poorly differentiated gastric carcinoma also known as limitis plastica-type carcinoma, is characterized by rapid cancer cell infiltration and proliferation accompanied by extensive stromal fibrosis (8). Common features of scirrhous gastric cancer include rapidly progressive invasion and a high frequency of metastasis to the peritoneum (9), which distinguishes it from intestinal types of gastric cancer (10). Scirrhous carcinoma, which represents approximately 10% of gastric carcinomas, shows a 5-year survival rate of 0% to 17%, compared with 35% to 70% for other types of gastric carcinomas (11). Various treatments, including chemotherapy, hormonal therapy,
heterothermia, and immunotherapy, have been tested for effectiveness in peritoneal metastasis from scirrhous gastric carcinoma, but the results have been unsatisfactory (12). Accordingly, novel therapies based on the characteristic biological behavior of scirrhous gastric cancer are urgently required. However, the mechanisms responsible for proliferation, particularly the mechanism underlying peritoneal metastasis, remain unclear. To elucidate these mechanisms, we needed to make a reliable scirrhous gastric carcinoma model in mice. We, thus, recently established a cell line, HSC-44PE, from patients with gastric scirrhous carcinomas (13). We have also isolated a cell line, 44As3, with high metastatic characteristics from the parental cells, HSC-44PE, by repeating cycles of orthotopic transplantation in nude mice, gathering cells from ascites, and further transplantation (14). The cell line 44As3, when orthotopically transplanted in the stomach wall of nude mice, will spontaneously develop peritoneal metastasis disseminated over the greater omentum, mesenterium, and parietal peritoneum with 100% incidence (14). This suggests that this animal model is reliable to use. The model also causes fatal cancerous peritonitis and bloody ascites in about 100% of cases (14).

Here, we identified several miRNAs (metastamirs) involved with peritoneal dissemination of scirrhous gastric cancers via an miRNA array (HSC–44PE vs. 44As3). Among the miRNAs, we focused on hsa-miR-516a-3p, whose expression is significantly lower in 44As3 compared with HSC-44PE. Moreover, using proteomics approaches (15, 16), we showed that the miRNA targets extracellular sulfatase 1 (SULF1) and the other unknown proteins in 44As3, and that the enzyme also regulates the Wnt signaling pathway in human scirrhous gastric cancer. Furthermore, we showed the feasibility of the miRNA for antimetastasis therapy of scirrhous gastric carcinomas in vivo.

Materials and Methods

Cells

HSC-44PE cells were previously established from a patient with scirrhous gastric cancer (13). Orthotopic implantation of HSC–44PE cells into BALB/c nude mice led to the dissemination of the tumor cells to the greater omentum, mesenterium, peritoneum, and so on, and caused ascites in a small number of animals. Cycles of isolation and orthotopic inoculation of the ascitic tumor cells were repeated in turn in the animals (12 cycles). We obtained a cell line (44As3) that possessed a high metastatic potential, with a strong capability of inducing ascites (14). All cells were cultured in RPMI 1640 with 10% FBS (13, 14).

Isolation of miRNA from the cells and miRNA microarray analysis

Total RNA was extracted from the cells using TRIzol Reagent (Invitrogen). Each total RNA (50 μg) was fractionated and cleaned up with the flashPAGE fractionator system (Ambion) to isolate miRNA fractions (17). Chemically synthesized oligoribonucleotides or purified miRNAs were labeled with a mirVana miRNA labeling kit (Ambion). Hybridization buffer (Ambion) was added to the fluorescently labeled miRNAs, and the solution was heated at 95°C for 3 minutes. Slides were hybridized for 16 hours at 42°C in sealed cassettes using a water bath. The slides were washed and dried prior to a high-resolution scan on a GenePix 4000B (Axon Instruments). Raw data were normalized and analyzed using Array-Pro Analyzer Version 4.5 (Media Cybernetics).

Northern blot analysis

The analysis was performed according to a previous report (18) with some modifications. Total RNA (20 μg) was separated on 12.5% denaturing (7 mol/L urea) PAGE and then transferred onto Biodyne Nylon Transfer Membranes (100 μm, Pall Corp.) using a vacuum blotting system (GE Healthcare). The membrane was dried and UV cross-linked. The probes modified with locked nucleic acid (LNA, Exiqon) were labeled with 32P (18, 19). The blots were prehybridized at 35°C for 30 minutes in hybridization buffer (GE Healthcare), and then each 32P-labeled LNA probe was added and incubated at 60°C for 2 hours. The membranes were washed twice in 2× SSC with 0.1% SDS at 60°C for 10 minutes. The probe sequences are as follows: hsa-miR-516a-3p, 5’- ACCCTCTGAAAGGAAGCA -3’; and U6 (control), 5’-CAGAATTTCGCTGTCATCCTT-3’. Total RNA from normal stomach was obtained from the FirstChoice Total RNA Human Normal Tissue Set (ABI).

Quantitative real-time reverse transcriptase PCR

TaqMan MicroRNA Assays were used to detect the expression levels of mature miRNAs. Ten nanograms of total RNA was reverse-transcribed with a TaqMan microRNA RT kit (ABI). All of the reverse transcriptase PCRs (RT-PCR) were run in triplicate, and miRNA expression, relative to small nuclear RNA (RNU6B), was calculated by the comparative ΔCt method (20).

Stable overexpression of hsa-miR-516a-3p in 44As3 cells

The hsa-miR-516a-3p expression vector (1 μg; Takara Bio) was transfected in 44As3 cells using a Lipofectamine-plus reagent as reported previously (21). Then, the cells were selected with Geneticin (100 μg/mL) to acquire a stable clone with overexpression of the miRNA (called 44As3-miR 516a-3p).

Proliferation, migration, and invasion analysis in vitro

The 44As3-miR-516a-3p was seeded onto a 96-well plate (0.5 × 104 cells/well) in RPMI 1640 with 10% FBS. On the next day, the cells were washed once with serum-free RPMI 1640. Cell proliferation was monitored with a cell counting kit (Dojin) as reported previously (22). Migration and invasion analysis was performed with BD BioCoat Angiogenesis System-Endothelial Cell Migration and BD BioCoat Fluoroblok Tumor Invasion System (BD Biosciences) according to the manufacturer’s instructions.

Primary tumor growth and survival rate in nude mice

The 44As3-miR-516a-3p (1.5 × 106 cells in 50 μL of RPMI 1640) was orthotopically inoculated into the middle wall of the greater curvature of the glandular portion of the stomach using a 29-gauge needle (Nipro) in BALB/c nude mice (6-week-old females) as described previously (14). Twenty days later,
the primary tumors were removed and weighed. Peritoneal dissemination to the omentum, mesenterium, and ascites was examined.

Animal experiments in the present study were performed in compliance with the guidelines of the Institute for Laboratory Animal Research at the National Cancer Center Research Institute or at Nagoya University Graduate School of Medicine.

**iTRAQ sample preparation and QSTAR Elite Hybrid LC-MS/MS**

The analysis was performed according to previous reports (15, 16) with some modifications. The cells were washed with PBS twice on the dish, collected with a cell scraper, and centrifuged. The pellet was vigorously washed with PBS. After centrifugation (15,000 revolutions per minute for 30 minutes at 4°C), the clarified supernatant was transferred to fresh microtubes and the total protein concentration was determined using the DC Protein Assay (Bio-Rad Laboratories). Each sample (100 μg protein) was digested with 0.2 mL of trypsin solution (50 μg/mL) at 37°C and labeled with the iTRAQ tags (113, 115, and 118: ABI) as summarized in Supplementary Fig. S1. After we combined the 3 labeled samples, QSTAR Elite Hybrid liquid chromatography/tandem mass spectrometry (LC MS/MS) and DiNa System driven by Analyst QS 2.0 software (Applied Biosystems-MDS SCIEX Ins) gave us the MS or MS/MS spectrum data. Finally, we determined the candidate proteins with ProteinPilot Software 2.0.1 (Applied Biosystems-MDS SCIEX Ins).

**Isolation of cytoplasmic and nuclear proteins from the cells**

Cytoplasmic and nuclear proteins were separately isolated using a ProteoJET Cytoplasmic and Nuclear Protein Extraction Kit (Fermentas Life Sciences).

**β-Catenin ELISA**

The total amount of β-catenin was determined using a DuoSet IC human total β-catenin ELISA kit (R&D Systems).

**TCF/LEF reporter assay**

To monitor the activity of the Wnt signal transduction pathway in the cells, a Cignal T-cell factor/lymphoid enhancer factor (TCF/LEF) Reporter Assay kit was used (SABiosciences). Thus, each cell was transfected with the TCF/LEF reporter using a Lipofectamine Plus kit (21). Sixteen hours later, the medium was changed to assay medium (Opti-MEM with 0.5% FBS, 0.1 mmol/L nonessential amino acids, and 1 mmol/L sodium pyruvate). At this time, we added LiCl (50 mmol/L, a GSK inhibitor) to the medium of HSC-44PE cells as a positive control. Dual-Luciferase assay (Promega) was performed 48 hours after the transfection. Promoter activity values are expressed as arbitrary units using a Renilla reporter for internal normalization (23).

**Plasmid DNA vector/atelocollagen complex preparation**

Atelocollagen was prepared from calf dermal collagen (Koken; refs. 24, 25). Atelocollagen is a liquid at 4°C and a gel at 37°C, when it is at a high concentration (≥0.5%). This biochemical feature of atelocollagen contributes to the controlled release of siRNA or plasmid DNA when injected directly into the tumor (24, 25). Furthermore, atelocollagen contributes to the increased stability of siRNA or plasmid DNA injected in tumors (21, 24–26). To prepare the plasmid DNA/ atelocollagen complex, equal volumes of atelocollagen in PBS and plasmid DNA solution were mixed by rotation for 20 minutes at 4°C (25).

**Antimetastasis therapy procedure**

44As3 cells (1.5 × 10⁶ cells in 50 μL of RPMI 1640) were orthotopically inoculated into the stomach wall of 6-week-old BALB/c nude mice (CLEA; ref. 14). After 10 days (day 0), we performed an intratumoral injection of the miR-516a-3p expression vector/atelocollagen complex or empty vector/atelocollagen complex under anesthesia. The final concentration of each vector/atelocollagen was 25 μg/20 μL per tumor in 0.5% atelocollagen. Five days later (on day 5), we repeated the injection. On day 15, we sacrificed the mice and excised the primary tumor. Total RNA or tissue lysate was prepared for further study. For the controls, HSC-44PE was orthotopically inoculated using the above-described method, but without any therapy, and then on day 15, the tumors were excised. The overall survival rate after the therapy was also examined (n = 20 mice in each group).

**Western blot analysis**

The analysis was performed according to our previous reports (22, 26–28). The following primary antibodies were used (Cell Signaling Japan): rabbit anti-human Wnt5a antibody, rabbit anti-human Wnt3a antibody, rabbit anti-human β-catenin antibody, α-tubulin, mouse anti-human α-tubulin antibody, and mouse anti-human histone H3 antibody, respectively. To detect SULF1, we used mouse anti-human sulfatase 1 antibody (Abcam). We used appropriate secondary antibody with horseradish peroxidase (Jackson ImmunoResearch Laboratories). Finally, the peroxidase activity was detected with an enhanced chemiluminescence detection system (GE Healthcare).

**Clinical samples**

The studies of clinical samples were conducted with institutional review board approval from Nagoya University School of Medicine. After obtaining appropriate informed consent from each patient, in accordance with the Declaration of Helsinki, tumor specimens were harvested. Details of the patients’ background was summarized in Supplementary Table S1. Normal stomach tissues were purchased from BioChain Institute, Inc. Each total RNA was extracted from the tissues, and quantitative real-time RT-PCR for miR-516a-3p was performed.

**Statistical analysis**

The data were analyzed using the Mann–Whitney U test. Probability values of less than 0.05 were considered to indicate significant differences.
Results

High frequency of peritoneal dissemination of scirrhous cancer results in miRNAome alteration

We performed miRNA microarray profiling between HSC-44PE and 44As3 (Table 1). As a result, 12 miRNAs were significantly upregulated and 24 miRNAs downregulated in 44As3 (the threshold was 1.5-fold up- or downregulation). These alterations of the miRNA levels were often observed in the human chromosomal location of 19q13.42 or 14q32.2.

Among the miRNAs, we focused on miR-516a-3p because the roles of the miRNA in both metastasis and tumorigenesis have not yet been elucidated at all. We performed both Northern blot analysis and quantitative RT-PCR to confirm the microarray (Fig. 1A and B). The miRNA in 44As3 was 3-fold downregulated compared with HSC-44PE. In the normal stomach, the miRNA showed 3-fold higher expression compared with HSC-44PE.

We have a cell pair from another scirrhous gastric cancer patient (called HSC-58, parental cell; and 58As9, high

<table>
<thead>
<tr>
<th>Rank</th>
<th>miRNA</th>
<th>Fold change</th>
<th>P value</th>
<th>Chromosomal location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased expression</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>hsa-miR-498</td>
<td>1.96</td>
<td>0.013</td>
<td>19q13.42</td>
</tr>
<tr>
<td>2</td>
<td>hsa-miR-505</td>
<td>1.95</td>
<td>0.014</td>
<td>Xq27.1</td>
</tr>
<tr>
<td>3</td>
<td>hsa-miR-519c-3p</td>
<td>1.93</td>
<td>0.021</td>
<td>19q13.42</td>
</tr>
<tr>
<td>4</td>
<td>mmu-miR-291b-3pb</td>
<td>1.88</td>
<td>0.022</td>
<td>7A1 (mouse)</td>
</tr>
<tr>
<td>5</td>
<td>hsa-miR-376b</td>
<td>1.88</td>
<td>0.030</td>
<td>14q32.2</td>
</tr>
<tr>
<td>6</td>
<td>hsa-miR-520d-5p</td>
<td>1.83</td>
<td>0.036</td>
<td>19q13.42</td>
</tr>
<tr>
<td>7</td>
<td>hsa-miR-522</td>
<td>1.78</td>
<td>0.031</td>
<td>19q13.42</td>
</tr>
<tr>
<td>8</td>
<td>mmu-miR-292-3pb</td>
<td>1.75</td>
<td>0.043</td>
<td>7A1 (mouse)</td>
</tr>
<tr>
<td>9</td>
<td>hsa-miR-514</td>
<td>1.65</td>
<td>0.037</td>
<td>Xq27.3</td>
</tr>
<tr>
<td>10</td>
<td>hsa-miR-95</td>
<td>1.62</td>
<td>0.035</td>
<td>4p16.1</td>
</tr>
<tr>
<td>11</td>
<td>hsa-miR-432</td>
<td>1.59</td>
<td>0.044</td>
<td>14q32.2</td>
</tr>
<tr>
<td>12</td>
<td>hsa-miR-502-5p</td>
<td>1.52</td>
<td>0.034</td>
<td>Xp11.23</td>
</tr>
</tbody>
</table>

| Decreased expression |
| 1    | hsa-miR-183 | −3.02       | 0.008   | 7q32.2               |
| 2    | hsa-miR-23a | −2.88       | 0.010   | 19p13.13             |
| 3    | hsa-miR-125a-5p | −2.74    | 0.010   | 19q13.42             |
| 4    | hsa-miR-516a-3p | −2.73    | 0.009   | 19q13.42             |
| 5    | hsa-miR-33a  | −2.72       | 0.011   | 22q13.2              |
| 6    | hsa-miR-16   | −1.97       | 0.013   | 13q14.2              |
| 7    | hsa-miR-106b | −1.92       | 0.018   | 7q22.1               |
| 8    | hsa-miR-140-5p| −1.89      | 0.029   | 16q22.1              |
| 9    | hsa-miR-345  | −1.87       | 0.019   | 14q32.2              |
| 10   | hsa-miR-93d  | −1.82       | 0.024   | 7q22.1               |
| 11   | hsa-miR-34a  | −1.82       | 0.022   | 1p36.22              |
| 12   | hsa-miR-370  | −1.81       | 0.039   | 14q32.2              |
| 13   | hsa-miR-129-3p| −1.78      | 0.020   | 11p11.2              |
| 14   | hsa-miR-17   | −1.77       | 0.036   | 13q31.3              |
| 15   | hsa-miR-27a | −1.71       | 0.021   | 19p13.13             |
| 16   | hsa-miR-450a | −1.66       | 0.037   | Xq26.3               |
| 17   | hsa-miR-100 | −1.61       | 0.033   | 11q24.1              |
| 18   | hsa-miR-31   | −1.61       | 0.039   | 9p21.3               |
| 19   | hsa-miR-193b| −1.60       | 0.036   | 16p13.12             |
| 20   | hsa-miR-330-5p| −1.59      | 0.048   | 19q13.32             |
| 21   | hsa-miR-200c | −1.56       | 0.032   | 12p13.31             |
| 22   | hsa-miR-27b  | −1.56       | 0.038   | 9q22.32              |
| 23   | hsa-miR-337-3p| −1.56      | 0.045   | 14q32.2              |
| 24   | hsa-miR-526b | −1.53       | 0.046   | 19q13.42             |

a Only those miRNAs whose expression levels showed greater than 1.5-fold increase or decrease in 44As3 cells are listed.

b,c,d miRNAs clustered together in pairs; each pair of 2 miRNAs is represented by the same footnote letter.
metastatic cell; ref. 14). According to the miRNA array, we obtained a similar result as showing significant decreased expression level of miR-516a-3p in 58As9, compared with HSC-58 (Supplementary Table S2). These consistent results from 2 cell pairs potently prompted us to further examine about miR-516a-3p.

Stable overexpression of miR-516a-3p in 44As3 reduced their proliferation rate, migration, and invasion in vitro

We prepared a stable cell line with overexpression of miR-516a-3p from 44As3 (called 44As3-miR-516a-3p). Northern blot analysis and qRT-PCR revealed the successful overexpression of the miRNA (Fig. 1C and D). 44As3-miR-516a-3p demonstrated lower cell proliferation, migration, and invasion compared with a 44As3-empty vector stably transfected one (Fig. 2A). In the other cell pair (HSC-58 and 58As9), we also prepared a stable cell line with overexpression of the miRNA from 58As9 (called 58As9-miR-516a-3p). The 58As9-miR-516a-3p cell line gave similar results, such as lower cell proliferation, migration, and invasion, compared with an empty vector–transfected control cell (Supplementary Fig. S2).

Fig. 2B shows the results when we orthotopically inoculated these 4 lines in the stomach wall of nude mice. Twenty days later, we observed the reduced tumor formation ratio there. Markedly, 44As3-miR-516a-3p showed that only 3 of the 12 mice that had formed tumors harbored ascitic fluid. We consistently observed the reduction of disseminated metastasis, that is, omentum or mesenterium, in the mice inoculated with the cell line (Fig. 2B). The cell line showed
significantly lighter tumors than those of 44As3 or 44As3-empty vector. The mice inoculated with 44As3-miR-516a-3p survived significantly longer than those of 44As3 and those of the 44As3-empty vector group.

**Extracellular SULF1 is a direct target of miR-516a-3p**

Proteomics analysis using an iTRAQ reagent and QSTAR Elite Hybrid LC-MS/MS simultaneously identified 11 candidate proteins as the targets of miR-516a-3p.
On the target prediction (TargetScan) in silico, 5 candidates did not appear, suggesting that these might be indirect targets of the miRNA. We focused on SULF1 as an attractive target, and then performed a luciferase reporter assay. Figure 3C showed that SULF1 is an actual target of the miRNA. The nucleotide sequences of SULF1 in the 3'-UTRs, which were predicted as a binding site of the miRNA, were highly conserved broadly beyond species (Supplementary Fig. S3). Western blot analysis (Fig. 3D) revealed that SULF1 expression was simply the inverse of that of miR-516a-3p by Northern blot analysis (Fig. 1). In the normal stomach, SULF1 protein was undetectable (Supplementary Fig. S4), probably as a result of regulation by the miRNA.

**miR-516a-3p indirectly regulates the Wnt pathway by targeting SULF1**

SULF1 is an extracellular sulfatase (29). It acts on internal glucosamine-6-sulfate removal within heparan sulfate proteoglycans (HSPG) and thereby modulates HSPG interactions...
miR-516a-3p Is a Novel Antimetastamir

with various signaling molecules (30–32). Indeed, SULF1 promotes Wnt signaling (30–32). We found increased secretion of both Wnt3a and Wnt5a in 44As3, but 44As3-miR-516a-3p revealed decreased secretion of the ligands (Fig. 4A). In the cytoplasmic fraction prepared from 44As3, the amount of β-catenin was increased, and thus β-catenin accumulated in the nucleus of 44As3. In contrast, 44As3-miR-516a-3p harbored a lesser amount of β-catenin in both the cytoplasmic and nuclear fraction compared with 44As3 (Fig. 4B and C). Among the cells, mRNA levels of Wnt3a, Wnt5a, and β-catenin did not change at all (Supplementary Fig. S5). Both mRNA and protein levels of Frizzled 4 and 5 also did not change (Fig. 4A and Supplementary Fig. S5). These results suggested that the miRNA did not alter the expression levels of those proteins. Finally, we showed activated TCF/LEF in 44As3 but decreased TCF/LEF activity in 44As3-miR-516a-3p, consistent with the series of results showing activated Wnt pathway (Fig. 4D).

Antimetastasis therapy against 44As3 orthotopic tumors

We showed that decreased miR-516a-3p expression in 44As3 orthotopic tumors is associated with the promotion of peritoneal dissemination of scirrhous gastric cancers. To assess the therapeutic effect of the miRNA, intratumoral treatment with miR-516a-3p vector with atelocollagen was examined (Fig. 5A). Atelocollagen was facilitated to deliver the plasmid DNA inside the cell (25). Compared with the empty vector control, the expression of the miRNA was higher via the intratumoral injection of the miR-516a-3p vector/atelocollagen complex, as shown by Northern blot analysis and qRT-PCR (Fig. 5B). Furthermore, SULF1 protein levels in the treated tumors were decreased (Fig. 5C), and significantly less ascitic fluid was pooled in the treated group. Finally, the overall survival period was longer in the treated group than in the control (Fig. 5D). In Supplementary Fig. S6, we observed green fluorescence from the pcAEGFP1-N1 vector with atelocollagen injected into the tumor in the same manner, confirming that our delivery method was functional.

Expression level of miR-516a-3p in clinical samples

Quantitative real-time RT-PCR revealed significant decreased expression level of miR-516a-3p in primary gastric cancer tissues from the patients with peritoneal dissemination, compared with that from the patients without peritoneal dissemination (Fig. 6). In stomach tissues from normal donors, we observed a high expression level of the miRNA.

Discussion

The major causes of death from cancer are complications arising from metastasis (33). Therefore, effective treatments targeting metastatic disease will improve morbidity and mortality among cancer patients. Despite many advances in knowledge from more than a century of researching metastasis, its molecular mechanisms are still not completely understood. Several reports have described the involvement of a recently discovered class of noncoding regulatory RNA, that is, miRNA, in the regulation of cancer (oncomir; ref. 34). More recently, a specialized family of miRNA, which Hurst and colleagues call metastamir (33), has been shown to have pro- and antimetastatic effects (35, 36). In the present article, we described many kinds of metastamirs, which are potently associated with peritoneal disseminations of scirrhous gastric carcinomas. Among the miRNAs, we focused on miR-516a-3p, whose expression was significantly lower in 44As3 than in HSC-44PE (Fig. 1A). A clone cell with stable overexpression of the miRNA demonstrated that the miRNA dramatically regulates cell mobility rather than cell proliferation. Upon orthotopic inoculation of 44As3-miR 516a-3p in the stomach wall in nude mice, we hardly observed ascitic fluids; this lack of fluids prolonged the survival of the mice. On the other hand, orthotopically inoculated mice with 44As3 rapidly pooled a large volume of ascitic fluids without exception, consistent with our previous report (14). These results strongly suggested that the miRNA is a genuine metastamir exhibiting antimetastatic effects (“antimetastamir”).

To identify the target protein of the miRNA, a proteomic analysis was performed by means of isobaric tagging for relative quantification using multidimensional LC MS/MS. iTRAQ-based LC-MS/MS provides a valuable platform for simultaneously identifying and quantifying target proteins of miRNAs. Indeed, we identified and quantified 11 proteins, including some whose functions are unknown. Unlike the conventional method (37), that is, 2-dimensional gel electrophoresis, and the peptide mass fingerprint method via matrix-assisted laser desorption/ionization—time-of-flight MS, the iTRAQ-based LC-MS/MS methods are much more accurate at identifying proteins and at enabling high-throughput tasks.

Here, we focused on SULF1 as a target of the miRNA, because extracellular sulfatases are crucial elements of the Wnt signaling pathway in cancers (32). SULF1 removes 6-O sulfates from HSPG chains to liberate Wnt ligands, and thus the liberated ligands enable binding to Frizzled receptors (30). Wnt signaling plays an important role in cancers, as reported many times (38). In patients with gastric cancers, Wnt5a is very frequently expressed (39); Wnt5a is stained in tumor cells but not in stromal cells. In addition, the 5-year survival rate is significantly low in patients with Wnt5a-positive gastric cancers (39). The expression of Wnt5a in gastric cancer cells could be critical for the migration and invasion of cancer cells from primary regions (40). Taken together, the previous and present results suggest that the expression of Wnt5a is correlated with the aggressiveness and poor prognosis of gastric cancer (39, 40). In the present study, secreted Wnt5a was increased in 44As3; in contrast, the secretion level was decreased in 44As3-miR-516a-3p. Wnt3a and Wnt5a activate the typical canonical pathway (the β-catenin pathway) in the cells (38, 41, 42). However, regarding Wnt5a in 44As3, we have another pathway to examine: the planar cell polarity (PCP; noncanonical) pathway (40), which should be initially proved by us in peritoneal dissemination of scirrhous gastric cancers. Overall, decreased miR-516a-3p upregulates SULF1, after which Wnt ligands, which were liberated by SULF1, activate at least the Wnt canonical pathway, finally leading to peritoneal dissemination. In that case, miR-516a-3p triggers a series of reactions. Of course, not only the other proteins determined in Fig. 3B, but...
Figure 4. miR-516a-3p regulates Wnt pathway via sulfatase1 expression. A, Western blot analysis of Wnt5a and Wnt5b ligands, Frizzled 4 and 5 were also examined. β-Actin was used as a loading control. Each lane was explained in a box. B, Western blot analysis of β-catenin of cytoplasmic and nuclear fraction. The bands on the blot were normalized with α-tubulin or Histone H3, respectively. The density ratios are shown in the graphs. C, total β-catenin amount was determined by a specific ELISA. The bars show means ± SD (n = 4), *, P < 0.05; ***, P < 0.001. D, TCF/LEF reporter assay. The bars show means ± SD (n = 4), ***, P < 0.001. LiCl (50 mmol/L) for positive controls as a GSK inhibitor was added to the culture of HSC-44PE cells. Firefly and Renilla luciferase activities were determined using a Dual-Luciferase Reporter Assay System, with firefly luciferase activities calculated as means ± SD after being normalized by Renilla luciferase activities.

Figure 5. Antimetastasis therapy using miR-516a-3p expression vector via atelocollagen-mediated delivery method. A, a therapy procedure. Nude mice bearing orthotopic 44As3 tumors were injected (intratumorally) with an empty vector or miR-516a-3p vector (25 μg) with atelocollagen (day 0). Five days later, the same therapy was repeated. On day 15, we excised the tumors for further study. B, Northern blot analysis (left) and real-time qPCR (right) were examined. Each lane is explained in box. All of the bars in B show means ± SD (n = 4). **, P < 0.01. C, Western blot analysis of human SULF1. Ratios of density, individually normalized with β-actin, are shown beneath the blot. D, volume of ascites (left). The bars show mean ± SD (n = 4). **, P < 0.01. Overall survival (right) of each of 20 mice was determined.
also the other miRNAs in Table 1, must be involved in and regulate peritoneal dissemination. To elucidate the strength of the influence of the other target proteins besides SULF1, we are generating the miR-516a-3p–resistant SULF1 construct by cloning the SULF1 cDNA from the start codon until the stop codon, thereby excluding the 3′–UTR region. It is our subsequent urgent task to determine the phenotypes such as proliferation, or in vivo peritoneal dissemination using the cell with overexpression of both miR-516a-3p and the above construct.

To elicit a therapeutic outcome, we indicated the feasibility of using the miR-516a-3p plasmid vector complexed with a biomaterial delivery reagent, atelocollagen, to inhibit peritoneal dissemination in a mouse model. Atelocollagen is a natural product prepared from bovine dermal collagen (24, 25). Atelocollagen shows neither antigenicity nor toxicity in animals, as antigenic telopeptides are eliminated by pepsin digestion (25). Atelocollagen is soluble at a lower temperature (below 10°C) but solidifies to refibrillation upon injection into an animal body (37°C). When plasmid DNA is embedded in atelocollagen, the quantity and period of gene expression are well controlled in vivo (25). Atelocollagen can protect plasmid DNA, antisense oligodeoxynucleotides, and siRNAs from degradation by several nucleases, proteases, and antibodies, thereby prolonging the half-life of embedded nucleic acids (21, 25, 27). In the present study, we successfully demonstrated that the intratumoral injection of miR-516a-3p vector with atelocollagen revealed its constitutive active expression in primary 44As3-tumors orthotopically inoculated in the stomach in nude mice. These findings demonstrate that miR-516a-3p, a novel antimi etastamir, can be a target for inhibiting peritoneal dissemination of scirrhou s gastric cancer. However, much work remains before it can be applied clinically. First, synthetic miRNA instead of the plasmid vector should be examined; second, a systemic delivery system of synthetic miRNA specific to tumors should be developed. Toward these ends we have acquired promising results, because we already have much knowledge about how to systematically deliver synthetic small RNA molecules, that is, siRNA, specifically to tumors (22). The systemic therapeutic effect by the synthetic double-stranded RNA mimicking miR-516a-3p complexed with atelocollagen will be described elsewhere in the near future.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Drs. Kazuo Kita, Takayuki Okubo, Manabu Harada, and Yasuhide Oyamato for their helpful suggestions regarding the experiments and the manuscript.

Grant Support

Grants-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (17016030) and from the Japan Society for the Promotion of Science (17798185, 19590273, and 21590305).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 13, 2010; revised November 22, 2010; accepted November 30, 2010; published OnlineFirst December 17, 2010.

References

11. Liu Y, Yoshimura K, Yamaguchi N, Shinmura K, Yokota J, Katai H. Cau-
seion of Bormann type 4 gastric cancer: heritable factors or en-
12. Samel S, Singal A, Becker H, Post S. Problems with intraoperative
carcinoma that possess the potential to metastasize spontaneously in nude mice. Cancer Sci 2004;95:875–82.
15. Lippert DN, Ralph SG, Phillips M, White R, Smith D, Hardie D, et al. Quan-
titative ITRAQ proteome and comparative transcriptome ana-
17. Reinhardt B, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, et al. The 21-nucleotide let-7 RNA regulates develop-
18. Váraliyay E, Burgár J, Havelda Z. MicroRNA detection by northern
electroporation: tumor vascularization correlates to delivery effi-
20. Uvak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2\(^{-}\Delta \Delta \text{CT}\) Method.
22. Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu K, Takei Y. Systemic delivery of siRNA specific to tumor mediated by atelocolla-
gen: combined therapy using siRNA targeting Bcl-xL and cisplatin
23. Sheff BA, Navarro SL, Hannah RR, Wood KV. Dual-Luciferase\textsuperscript{x} reporter assay: an advanced coporter technology integrating firefly
24. Takei Y, Kadomatsu K. In vivo delivery of nucleic acid compounds using atelocollagen: its use in cancer therapeutics tar-
26. Takei Y, Kadomatsu K, Goto T, Muramatsu T. Combinational anti-
33. Hurst DR, Edmonds MD, Welch DR. Metastamir: the field of metas-
35. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metas-
37. Herzel WJ, Billeci TM, Stults JT, et al. Identifying proteins from two-
dimensional gels by molecular mass searching of peptide fragments
42. Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits beta-
The Metastasis-Associated microRNA miR-516a-3p Is a Novel Therapeutic Target for Inhibiting Peritoneal Dissemination of Human Scirrhous Gastric Cancer

Yoshifumi Takei, Misato Takigahira, Keichiro Mihara, et al.

Cancer Res  Published OnlineFirst December 17, 2010.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-10-2530

Supplementary Material  Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2010/12/17/0008-5472.CAN-10-2530.DC1

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/early/2011/02/01/0008-5472.CAN-10-2530. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.